Table 2.
Baseline demographic and disease characteristics*
| PBO (n = 156) | CANA 100 mg (n = 157) | CANA 300 mg (n = 156) | Total (n = 469) | |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Men | 76 (48.7) | 76 (48.4) | 87 (55.8) | 239 (51.0) |
| Women | 80 (51.3) | 81 (51.6) | 69 (44.2) | 230 (49.0) |
| Age (years) | 56.8 ± 8.3 | 57.4 ± 10.5 | 56.1 ± 8.9 | 56.8 ± 9.3 |
| Race, n (%)† | ||||
| White | 128 (82.1) | 132 (84.1) | 127 (81.4) | 387 (82.5) |
| Black or African American | 10 (6.4) | 5 (3.2) | 11 (7.1) | 26 (5.5) |
| Asian | 2 (1.3) | 2 (1.3) | 0 | 4 (0.9) |
| Other‡ | 16 (10.3) | 18 (11.5) | 18 (11.5) | 52 (11.1) |
| HbA1c (%) | 8.1 ± 0.9 | 8.1 ± 0.9 | 8.1 ± 0.9 | 8.1 ± 0.9 |
| FPG (mmol/l) | 9.4 ± 2.2 | 9.6 ± 2.3 | 9.3 ± 2.1 | 9.5 ± 2.2 |
| Body weight (kg) | 91.2 ± 22.6 | 93.8 ± 22.6 | 93.5 ± 22.0 | 92.8 ± 22.4 |
| BMI (kg/m2) | 32.7 ± 6.8 | 33.3 ± 6.3 | 33.2 ± 6.3 | 33.1 ± 6.5 |
| Duration of T2DM (years) | 10.3 ± 6.7 | 9.0 ± 5.7 | 9.4 ± 6.4 | 9.6 ± 6.3 |
PBO, placebo; CANA, canagliflozin; FPG, fasting plasma glucose; BMI, body mass index; T2DM, type 2 diabetes mellitus; SD, standard deviation.
*
Data are mean ± SD unless otherwise indicated.
†
Percentages may not total 100.0% because of rounding.
‡
Includes American Indian or Alaska Native, Native Hawaiian or other Pacific islander, multiple, other, or not reported.